| Literature DB >> 15243972 |
M Tschöp1, T R Castañeda, H G Joost, C Thöne-Reineke, S Ortmann, S Klaus, M M Hagan, P C Chandler, K D Oswald, S C Benoit, R J Seeley, K P Kinzig, T H Moran, A G Beck-sickinger, N Koglin, R J Rodgers, J E Blundell, Y Ishii, A H Beattie, P Holch, D B Allison, K Raun, K Madsen, B S Wulff, C E Stidsen, M Birringer, O J Kreuzer, M Schindler, K Arndt, K Rudolf, M Mark, X Y Deng, D C Whitcomb, H Halem, J Taylor, J Dong, R Datta, M Culler, S Craney, D Flora, D Smiley, M L Heiman, D C Withcomb.
Abstract
Batterham et al. report that the gut peptide hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al. cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3-36.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15243972 DOI： 10.1038/nature02665
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962